Clinical trials: Pharmacokinetic Study
Healthy Volunteer
To Study the Pharmacokinetic and Cardiovascular Effects of Propofol With Respect to Pharmacogenetics in Pakistani Population
This study aimed to determine the effects of genetic variabilities among the Pakistani population on propofol serum concentration and its adverse effects mainly cardiovascular adverse effects.
- Trial name
- NCT05383534
- Testing
- Propofol Injection
- Where
- Pakistan
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Parkinson's Disease
Pharmacokinetic Study in Healthy Volunteers
Phase I open, randomized cross-over pharmacokinetic study.
- Trial name
- NOCOFPK2 (NCT02554734)
- Testing
- levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone
- Where
- Finland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Asthma, Diabetes Mellitus
A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics
This study will compare the rate and extent of absorption of TI Inhalation Powder in subjects with asthma and subjects with normal lung function. 24 eligible subjects will be enrolled into the treatment phase of the trial.
- Trial name
- NCT00673621
- Testing
- Technosphere Insulin Inhalation Powder, Salbutamol (Albuterol), Methacholine chloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Pharmacokinetic, Olverembatinib
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
This is a non-randomized, open-label, parallel, single-dose study to evaluate the pharmacokinetic profile of olverembatinib in participants with normal or impaired liver function.
- Trial name
- NCT07282093
- Testing
- Olverembatinib 20mg
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ascentage Pharma Group Inc.
Postbariatric Hypoglycemia
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses and Drug Drug Interaction of MBX 1416 in healthy volunteers This study includes 3 parts.
- Trial name
- NCT06036784
- Testing
- MBX 1416 (Part A), MBX 1416 (Part B), MBX 1416 (Part C)
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- MBX Biosciences
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and…
- Trial name
- NCT02113163
- Testing
- Metformin Eicosapentaenoate, Metformin HCl and Vascepa
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Thetis Pharmaceuticals LLC
Healthy Male Adult Volunteers
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®
Study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS(L), US-Humalog®, and EU-Humalog®
- Trial name
- NCT07165652
- Testing
- NKF-INS(L), US-Humalog®, EU-Humalog®
- Where
- South Africa
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Xentria, Inc.
Advanced Solid Malignancies
Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors
The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B continuously.
- Trial name
- NCT01455584
- Testing
- HM781-36B tablets
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Alzheimer Disease
Tricaprilin Liquid Formulation PK Study
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of new liquid formulations of tricaprilin, with the aim of finding a suitable formulation to advance in development.
- Trial name
- NCT05028114
- Testing
- AC-1202, AC-OLE-01, AC-OLE-02
- Where
- Australia
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Cerecin
Healthy Male Volunteer
A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers
Study Design : randomized, open label, single-dose, 2-way cross-over design Phase : Phase I
- Trial name
- NCT01776047
- Testing
- Exforge®, G-0081
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Healthy Adult Subjects
A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects.
The Goal of these study is to assess the comparative pharmacokinetics of Test Product (A): ADL-018 Injection 150 mg/mL solution in a single dose pre-filled autoinjector, manufactured by Kashiv Biosciences LLC, USA with Reference…
- Trial name
- NCT06929052
- Testing
- ADL-018 Autoinjector, ADL-018 Injection
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Health Adult Subjects
Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11
This is a randomized, double-blind, parallel-controlled study to compare the PK profile of HLX29 and HLX11 and evaluate their safety, tolerability, and immunogenicity after a single intravenous dose in healthy male adult…
- Trial name
- NCT07776132
- Testing
- HLX29, HLX11
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Diabetes Mellitus, Type 2
Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function
Primary objective: To compare the pharmacokinetic profile of Glymera (PB1023) Injection after a single dose administered by subcutaneous injection to subjects with normal renal function and impaired renal function.
- Trial name
- NCT01478399
- Testing
- PB1023 Injection
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Unspecified Adult Solid Tumor, Protocol Specific
R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005990
- Testing
- tipifarnib, topotecan hydrochloride
- Where
- United States
- Sponsor
- NYU Langone Health
Healthy
HS-10542 Study in Healthy Participants
This is a randomized, double-blind, placebo-controlled, dose escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and the food effect on the pharmacokinetics of HS-10542 in healthy…
- Trial name
- NCT07040046
- Testing
- HS-10542
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hemophilia A
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
This is an open-label, non-randomized, efficacy, safety and pharmacokinetic (PK) study comparing octocog alfa and rVIII-SingleChain.
- Trial name
- NCT01486927
- Testing
- rVIII-SingleChain, Octocog alfa
- Where
- 56 sites in United States, Australia and 18 more
- Volunteers
- 175 people
- Sponsor
- CSL Behring
Dyslipidemias
Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A
To evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A
- Trial name
- NCT04874142
- Testing
- YYC506-T, YYC506-A, YYC506-T + YYC506-A
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Healthy Female Adult Volunteers
A Study to Investigate the Pharmacokinetics and Safety of KM04 Compared to United States (US)-Gonal-f Revised Formulation Female (RFF) Redi-ject and European Union (EU)-Gonal-f in Healthy Adult Female Volunteers
A study to investigate the pharmacokinetics and safety of KM04 compared to United States (US)-Gonal-f Revised Formulation Female (RFF) Redi-ject and European Union (EU)-Gonal-f in healthy adult female volunteers
- Trial name
- NCT07794683
- Testing
- KM04, Unites States (US)-Gonal-f® Revised Formulation Female (RFF) Redi-ject®, European Union (EU)-Gonal-f®
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Xentria, Inc.
Healthy Subjects, Anaemia
A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects
This is a first time in human study to investigate the safety of GSK626616AC given as oral single and repeat doses in healthy subjects.
- Trial name
- NCT00443170
- Testing
- omeprazole, caffeine, flurbiprofen, rosiglitazone
- Where
- 3 sites in Australia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline